Haemonetics Stock Z Score

HAE Stock

USD 93.33 1.20 1.30%

Altman Z Score is one of the simplest fundamental models to determine how likely your company is to fail. The module uses available fundamental data of a given equity to approximate the Altman Z score. Altman Z Score is determined by evaluating five fundamental price points available from the company's current public disclosure documents. Check out Haemonetics Piotroski F Score and Haemonetics Valuation analysis.

For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.

At present, Haemonetics' Change In Working Capital is projected to increase significantly based on the last few years of reporting. The current year's Capital Expenditures is expected to grow to about 133.1 M, whereas Net Working Capital is forecasted to decline to about 380.9 M. At present, Haemonetics' Gross Profit is projected to increase significantly based on the last few years of reporting. The current year's Operating Income is expected to grow to about 188.4 M, whereas Cost Of Revenue is forecasted to decline to about 318.9 M.

Haemonetics Company Z Score Analysis

Haemonetics' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..

Z Score

Sum Of

5 Factors

More About Z Score | All Equity Analysis

First Factor

1.2 * (

Working Capital

/

Total Assets )

Second Factor

1.4 * (

Retained Earnings

/

Total Assets )

Thrid Factor

3.3 * (

EBITAD

/

Total Assets )

Fouth Factor

0.6 * (

Market Value of Equity

/

Total Liabilities )

Fifth Factor

0.99 * (

Revenue

/

Total Assets )

Haemonetics Z Score Driver Correlations

Understanding the fundamental principles of building solid financial models for Haemonetics is extremely important. It helps to project a fair market value of Haemonetics Stock properly, considering its historical fundamentals such as Z Score. Since Haemonetics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Haemonetics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Haemonetics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Short Term Investments	Common Stock	Long Term Debt	Good Will	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Accumulated Depreciation	Short Long Term Debt	Cash And Equivalents	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.61	0.86	0.24	0.91	0.59	0.96	0.97	0.04	0.92	-0.6	0.57	0.91	0.97	0.52	0.3	-0.83	0.92	0.74	0.59	-0.32	-0.56	0.69	-0.78	0.69	-0.6
Total Stockholder Equity	0.61		0.29	0.63	0.59	0.87	0.44	0.63	0.13	0.59	-0.85	0.64	0.35	0.53	0.77	-0.03	-0.37	0.38	0.44	0.39	-0.57	-0.28	0.34	-0.18	0.23	0.06
Net Debt	0.86	0.29		-0.1	0.69	0.33	0.95	0.75	0.04	0.86	-0.23	0.61	0.94	0.92	0.39	0.65	-0.94	0.94	0.73	0.61	-0.21	-0.58	0.68	-0.81	0.71	-0.51
Retained Earnings	0.24	0.63	-0.1		0.18	0.36	0.01	0.25	-0.16	0.31	-0.56	0.1	0.04	0.2	0.26	-0.39	0.08	0.06	-0.31	0.24	-0.24	0.23	-0.13	0.2	-0.35	-0.02
Accounts Payable	0.91	0.59	0.69	0.18		0.7	0.84	0.93	0.12	0.71	-0.63	0.59	0.75	0.82	0.6	0.28	-0.62	0.77	0.74	0.34	-0.35	-0.55	0.64	-0.6	0.66	-0.59
Net Receivables	0.59	0.87	0.33	0.36	0.7		0.46	0.64	0.14	0.44	-0.79	0.72	0.37	0.46	0.81	0.16	-0.33	0.39	0.57	0.21	-0.56	-0.37	0.39	-0.14	0.38	0.0
Total Liab	0.96	0.44	0.95	0.01	0.84	0.46		0.91	0.04	0.89	-0.4	0.55	0.96	0.98	0.41	0.44	-0.91	0.97	0.8	0.62	-0.21	-0.58	0.76	-0.88	0.79	-0.61
Total Current Assets	0.97	0.63	0.75	0.25	0.93	0.64	0.91		0.05	0.84	-0.66	0.48	0.84	0.91	0.46	0.13	-0.74	0.85	0.72	0.52	-0.3	-0.5	0.68	-0.74	0.69	-0.61
Short Term Debt	0.04	0.13	0.04	-0.16	0.12	0.14	0.04	0.05		0.03	-0.18	0.31	-0.2	0.02	0.2	0.25	-0.09	-0.19	0.22	-0.42	-0.37	0.03	0.12	0.04	-0.16	0.24
Intangible Assets	0.92	0.59	0.86	0.31	0.71	0.44	0.89	0.84	0.03		-0.52	0.57	0.87	0.96	0.43	0.32	-0.91	0.88	0.59	0.72	-0.36	-0.4	0.56	-0.74	0.53	-0.41
Short Term Investments	-0.6	-0.85	-0.23	-0.56	-0.63	-0.79	-0.4	-0.66	-0.18	-0.52		-0.52	-0.28	-0.46	-0.7	0.16	0.29	-0.31	-0.37	-0.11	0.72	0.38	-0.11	0.1	-0.11	0.06
Common Stock	0.57	0.64	0.61	0.1	0.59	0.72	0.55	0.48	0.31	0.57	-0.52		0.46	0.53	0.88	0.72	-0.55	0.48	0.66	0.2	-0.62	-0.54	0.33	-0.2	0.33	0.02
Long Term Debt	0.91	0.35	0.94	0.04	0.75	0.37	0.96	0.84	-0.2	0.87	-0.28	0.46		0.95	0.33	0.43	-0.88	1.0	0.69	0.73	-0.09	-0.55	0.72	-0.86	0.79	-0.65
Good Will	0.97	0.53	0.92	0.2	0.82	0.46	0.98	0.91	0.02	0.96	-0.46	0.53	0.95		0.42	0.36	-0.9	0.96	0.7	0.7	-0.24	-0.5	0.72	-0.84	0.69	-0.58
Property Plant Equipment	0.52	0.77	0.39	0.26	0.6	0.81	0.41	0.46	0.2	0.43	-0.7	0.88	0.33	0.42		0.42	-0.32	0.35	0.61	0.12	-0.63	-0.65	0.3	-0.09	0.28	0.04
Current Deferred Revenue	0.3	-0.03	0.65	-0.39	0.28	0.16	0.44	0.13	0.25	0.32	0.16	0.72	0.43	0.36	0.42		-0.5	0.42	0.51	0.09	-0.21	-0.43	0.33	-0.26	0.34	-0.09
Net Tangible Assets	-0.83	-0.37	-0.94	0.08	-0.62	-0.33	-0.91	-0.74	-0.09	-0.91	0.29	-0.55	-0.88	-0.9	-0.32	-0.5		-0.89	-0.71	-0.7	0.3	0.46	-0.63	0.83	-0.68	0.34
Long Term Debt Total	0.92	0.38	0.94	0.06	0.77	0.39	0.97	0.85	-0.19	0.88	-0.31	0.48	1.0	0.96	0.35	0.42	-0.89		0.7	0.72	-0.11	-0.56	0.72	-0.86	0.78	-0.65
Capital Surpluse	0.74	0.44	0.73	-0.31	0.74	0.57	0.8	0.72	0.22	0.59	-0.37	0.66	0.69	0.7	0.61	0.51	-0.71	0.7		0.35	-0.25	-0.76	0.77	-0.73	0.86	-0.34
Deferred Long Term Liab	0.59	0.39	0.61	0.24	0.34	0.21	0.62	0.52	-0.42	0.72	-0.11	0.2	0.73	0.7	0.12	0.09	-0.7	0.72	0.35		0.08	-0.16	0.55	-0.66	0.57	-0.22
Accumulated Depreciation	-0.32	-0.57	-0.21	-0.24	-0.35	-0.56	-0.21	-0.3	-0.37	-0.36	0.72	-0.62	-0.09	-0.24	-0.63	-0.21	0.3	-0.11	-0.25	0.08		0.31	0.16	-0.15	0.1	-0.36
Short Long Term Debt	-0.56	-0.28	-0.58	0.23	-0.55	-0.37	-0.58	-0.5	0.03	-0.4	0.38	-0.54	-0.55	-0.5	-0.65	-0.43	0.46	-0.56	-0.76	-0.16	0.31		-0.42	0.47	-0.59	0.35
Cash And Equivalents	0.69	0.34	0.68	-0.13	0.64	0.39	0.76	0.68	0.12	0.56	-0.11	0.33	0.72	0.72	0.3	0.33	-0.63	0.72	0.77	0.55	0.16	-0.42		-0.84	0.85	-0.46
Net Invested Capital	-0.78	-0.18	-0.81	0.2	-0.6	-0.14	-0.88	-0.74	0.04	-0.74	0.1	-0.2	-0.86	-0.84	-0.09	-0.26	0.83	-0.86	-0.73	-0.66	-0.15	0.47	-0.84		-0.85	0.62
Net Working Capital	0.69	0.23	0.71	-0.35	0.66	0.38	0.79	0.69	-0.16	0.53	-0.11	0.33	0.79	0.69	0.28	0.34	-0.68	0.78	0.86	0.57	0.1	-0.59	0.85	-0.85		-0.49
Capital Stock	-0.6	0.06	-0.51	-0.02	-0.59	0.0	-0.61	-0.61	0.24	-0.41	0.06	0.02	-0.65	-0.58	0.04	-0.09	0.34	-0.65	-0.34	-0.22	-0.36	0.35	-0.46	0.62	-0.49

Click cells to compare fundamentals

To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.

Competition

Predict Haemonetics

According to the company's disclosures, Haemonetics has a Z Score of 0.0. This is 100.0% lower than that of the Health Care Equipment & Supplies sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.

Haemonetics Institutional Holders

Institutional Holdings refers to the ownership stake in Haemonetics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Haemonetics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Haemonetics' value.

		Shares
Dimensional Fund Advisors, Inc.	2023-12-31	826.7 K
Amvescap Plc.	2023-12-31	715.9 K
Westfield Capital Management Company, Lp	2023-12-31	712.1 K
Btim Corp		711.9 K
Fisher Asset Management, Llc	2023-12-31	711.7 K
Boston Partners Global Investors, Inc	2023-12-31	707.4 K
Schroder Investment Management Group	2023-12-31	656.8 K
Northern Trust Corp	2023-12-31	628.5 K
Charles Schwab Investment Management Inc	2023-12-31	534.7 K
Capital Research Global Investors	2023-12-31	6.5 M
Blackrock Inc	2023-12-31	6 M

Haemonetics Fundamentals

	Return On Equity	0.15
	Return On Asset	0.0612
	Profit Margin	0.1 %
	Operating Margin	0.16 %
	Current Valuation	5.35 B
	Shares Outstanding	50.79 M
	Shares Owned By Insiders	0.76 %
	Shares Owned By Institutions	99.24 %
	Number Of Shares Shorted	2.24 M
	Price To Earning	50.35 X
	Price To Book	4.59 X
	Price To Sales	3.41 X
	Revenue	1.17 B
	Gross Profit	530.77 M
	EBITDA	249.34 M
	Net Income	115.4 M
	Cash And Equivalents	284.47 M
	Cash Per Share	4.79 X
	Total Debt	765.89 M
	Debt To Equity	1.12 %
	Current Ratio	2.73 X
	Book Value Per Share	18.57 X
	Cash Flow From Operations	273.06 M
	Short Ratio	5.08 X
	Earnings Per Share	2.46 X
	Price To Earnings To Growth	1.63 X
	Target Price	105.57
	Number Of Employees	3.03 K
	Beta	0.36
	Market Capitalization	4.67 B
	Total Asset	1.93 B
	Retained Earnings	253.17 M
	Working Capital	517.91 M
	Current Asset	488.09 M
	Current Liabilities	185.55 M
	Net Asset	1.93 B

About Haemonetics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Haemonetics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Haemonetics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Haemonetics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Haemonetics is a strong investment it is important to analyze Haemonetics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Haemonetics' future performance. For an informed investment choice regarding Haemonetics Stock, refer to the following important reports:

How To Invest In Haemonetics

Details

Is Haemonetics Stock a good investment?

Details

What is Haemonetics' Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Haemonetics Piotroski F Score and Haemonetics Valuation analysis.

For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.

Note that the Haemonetics information on this page should be used as a complementary analysis to other Haemonetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

Complementary Tools for Haemonetics Stock analysis

When running Haemonetics' price analysis, check to measure Haemonetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Haemonetics is operating at the current time. Most of Haemonetics' value examination focuses on studying past and present price action to predict the probability of Haemonetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Haemonetics' price. Additionally, you may evaluate how the addition of Haemonetics to your portfolios can decrease your overall portfolio volatility.

	Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments
	Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments
	Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules
	Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios
	Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios
	Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments
	Commodity Channel Use Commodity Channel Index to analyze current equity momentum
	Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
	CEOs Directory Screen CEOs from public companies around the world
	FinTech Suite Use AI to screen and filter profitable investment opportunities
	Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets

Is Haemonetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Haemonetics. If investors know Haemonetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Haemonetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.05)

Earnings Share

2.46

Revenue Per Share

25.092

Quarterly Revenue Growth

0.101

Return On Assets

0.0612

The market value of Haemonetics is measured differently than its book value, which is the value of Haemonetics that is recorded on the company's balance sheet. Investors also form their own opinion of Haemonetics' value that differs from its market value or its book value, called intrinsic value, which is Haemonetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Haemonetics' market value can be influenced by many factors that don't directly affect Haemonetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Haemonetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Haemonetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Haemonetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Haemonetics Stock Z Score

Haemonetics Company Z Score Analysis

Z Score

Sum Of

5 Factors

First Factor

1.2 * (

Working Capital

/

Total Assets )

Second Factor

1.4 * (

Retained Earnings

/

Total Assets )

Thrid Factor

3.3 * (

EBITAD

/

Total Assets )

Fouth Factor

0.6 * (

Market Value of Equity

/

Total Liabilities )

Fifth Factor

0.99 * (

Revenue

/

Total Assets )

Haemonetics Z Score Driver Correlations

Haemonetics Institutional Holders

Haemonetics Fundamentals

About Haemonetics Fundamental Analysis

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Haemonetics Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY